Femasys Inc (FEMY)

$1.16

+0.01

(+0.87%)▲

Live

Insights on Femasys Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 213.11K → 271.14K (in $), with an average increase of 21.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -4.41M → -3.59M (in $), with an average increase of 22.5% per quarter

Performance

  • $1.14
    $1.23
    $1.16
    downward going graph

    1.72%

    Downside

    Day's Volatility :7.32%

    Upside

    5.69%

    downward going graph
  • $0.25
    $4.75
    $1.16
    downward going graph

    78.63%

    Downside

    52 Weeks Volatility :94.78%

    Upside

    75.58%

    downward going graph

Returns

PeriodFemasys IncIndex (Russel 2000)
3 Months
-48.2%
0.0%
6 Months
27.78%
0.0%
1 Year
55.38%
0.0%
3 Years
-90.42%
-22.6%

Highlights

Market Capitalization
25.8M
Book Value
$0.71
Earnings Per Share (EPS)
-0.85
Wall Street Target Price
10.0
Profit Margin
0.0%
Operating Margin TTM
-1277.07%
Return On Assets TTM
-48.8%
Return On Equity TTM
-106.57%
Revenue TTM
1.0M
Revenue Per Share TTM
0.06
Quarterly Revenue Growth YOY
-7.8%
Gross Profit TTM
764.3K
EBITDA
-14.5M
Diluted Eps TTM
-0.85
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.69
EPS Estimate Next Year
-0.4
EPS Estimate Current Quarter
-0.19
EPS Estimate Next Quarter
-0.17

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Femasys Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 762.07%

Current $1.16
Target $10.00

Company Financials

FY19Y/Y Change
Revenue
929.1K
-
Net Income
-11.3M
-
Net Profit Margin
-1.2K%
-
FY20Y/Y Change
Revenue
1.0M
↑ 11.72%
Net Income
-6.9M
↓ 38.65%
Net Profit Margin
-666.24%
↑ 547.02%
FY21Y/Y Change
Revenue
1.2M
↑ 13.66%
Net Income
-7.5M
↑ 9.01%
Net Profit Margin
-638.97%
↑ 27.27%
FY22Y/Y Change
Revenue
1.2M
↑ 2.25%
Net Income
-11.4M
↑ 51.16%
Net Profit Margin
-944.62%
↓ 305.65%
FY23Y/Y Change
Revenue
1.1M
↓ 11.13%
Net Income
-14.2M
↑ 25.04%
Net Profit Margin
-1.3K%
↓ 384.44%
Q4 FY22Q/Q Change
Revenue
234.2K
↓ 32.58%
Net Income
-2.9M
↓ 0.49%
Net Profit Margin
-1.2K%
↓ 398.47%
Q1 FY23Q/Q Change
Revenue
294.0K
↑ 25.5%
Net Income
-2.9M
↓ 1.44%
Net Profit Margin
-970.29%
↑ 265.26%
Q2 FY23Q/Q Change
Revenue
320.5K
↑ 9.02%
Net Income
-2.9M
↑ 1.44%
Net Profit Margin
-902.77%
↑ 67.52%
Q3 FY23Q/Q Change
Revenue
244.4K
↓ 23.76%
Net Income
-4.0M
↑ 38.13%
Net Profit Margin
-1.6K%
↓ 732.89%
Q4 FY23Q/Q Change
Revenue
213.1K
↓ 12.79%
Net Income
-4.4M
↑ 10.35%
Net Profit Margin
-2.1K%
↓ 433.9%
Q1 FY24Q/Q Change
Revenue
271.1K
↑ 27.23%
Net Income
-3.6M
↓ 18.39%
Net Profit Margin
-1.3K%
↑ 742.01%
FY19Y/Y Change
Total Assets
12.6M
-
Total Liabilities
58.0M
-
FY20Y/Y Change
Total Assets
7.6M
↓ 39.85%
Total Liabilities
59.4M
↑ 2.42%
FY21Y/Y Change
Total Assets
28.6M
↑ 275.7%
Total Liabilities
2.2M
↓ 96.22%
FY22Y/Y Change
Total Assets
16.9M
↓ 40.88%
Total Liabilities
1.7M
↓ 26.34%
FY23Y/Y Change
Total Assets
27.8M
↑ 64.28%
Total Liabilities
9.4M
↑ 468.84%
Q4 FY22Q/Q Change
Total Assets
16.9M
↓ 15.66%
Total Liabilities
1.7M
↓ 18.38%
Q1 FY23Q/Q Change
Total Assets
13.9M
↓ 17.92%
Total Liabilities
1.5M
↓ 8.57%
Q2 FY23Q/Q Change
Total Assets
14.3M
↑ 3.22%
Total Liabilities
1.4M
↓ 4.87%
Q3 FY23Q/Q Change
Total Assets
14.9M
↑ 3.77%
Total Liabilities
4.4M
↑ 206.72%
Q4 FY23Q/Q Change
Total Assets
27.8M
↑ 86.86%
Total Liabilities
9.4M
↑ 113.23%
Q1 FY24Q/Q Change
Total Assets
24.4M
↓ 12.2%
Total Liabilities
8.8M
↓ 6.8%
FY19Y/Y Change
Operating Cash Flow
-11.0M
-
Investing Cash Flow
12.3M
-
Financing Cash Flow
-127.8K
-
FY20Y/Y Change
Operating Cash Flow
-4.9M
↓ 55.18%
Investing Cash Flow
968.3K
↓ 92.14%
Financing Cash Flow
871.6K
↓ 782.14%
FY21Y/Y Change
Operating Cash Flow
-7.9M
↑ 60.77%
Investing Cash Flow
-306.9K
↓ 131.69%
Financing Cash Flow
29.7M
↑ 3307.16%
FY22Y/Y Change
Operating Cash Flow
-10.7M
↑ 35.32%
Investing Cash Flow
-407.5K
↑ 32.79%
Financing Cash Flow
-681.6K
↓ 102.3%
Q4 FY22Q/Q Change
Operating Cash Flow
-2.9M
↑ 5.04%
Investing Cash Flow
-93.9K
↑ 406.35%
Financing Cash Flow
-82.0K
↓ 77.36%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.6M
↓ 7.68%
Investing Cash Flow
-62.9K
↓ 32.95%
Financing Cash Flow
-144.1K
↑ 75.79%
Q2 FY23Q/Q Change
Operating Cash Flow
-2.7M
↑ 3.53%
Investing Cash Flow
-62.9K
↑ 0.0%
Financing Cash Flow
3.3M
↓ 2423.9%

Technicals Summary

Sell

Neutral

Buy

Femasys Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Femasys Inc
Femasys Inc
-14.81%
27.78%
55.38%
-90.42%
-90.42%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
5.43%
29.51%
27.2%
45.72%
155.38%
Resmed Inc.
Resmed Inc.
-4.4%
28.39%
-6.63%
1.01%
81.81%
Becton, Dickinson And Company
Becton, Dickinson And Company
0.96%
0.53%
-5.96%
-0.76%
1.54%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-10.32%
-6.31%
-4.27%
-1.41%
182.66%
Alcon Ag
Alcon Ag
11.48%
22.41%
13.04%
27.67%
52.06%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Femasys Inc
Femasys Inc
NA
NA
NA
-0.69
-1.07
-0.49
NA
0.71
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
72.45
72.45
7.13
6.29
0.16
0.08
NA
39.37
Resmed Inc.
Resmed Inc.
32.26
32.26
1.75
7.73
0.22
0.12
0.01
31.52
Becton, Dickinson And Company
Becton, Dickinson And Company
49.78
49.78
1.34
13.05
0.05
0.03
0.02
88.74
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
43.66
43.66
6.72
7.76
0.21
0.11
0.0
36.72
Alcon Ag
Alcon Ag
42.24
42.24
4.59
3.07
0.05
0.02
0.0
42.13
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Femasys Inc
Femasys Inc
Buy
$25.8M
-90.42%
NA
0.0%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$142.6B
155.38%
72.45
27.16%
Resmed Inc.
Resmed Inc.
Buy
$30.8B
81.81%
32.26
20.91%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$67.0B
1.54%
49.78
6.76%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$24.3B
182.66%
43.66
19.42%
Alcon Ag
Alcon Ag
Buy
$44.0B
52.06%
42.24
10.96%

Institutional Holdings

  • CM Management, LLC

    1.80%

  • Clear Creek Investment Mgmt LLC

    1.39%

  • Vanguard Group Inc

    0.87%

  • Geode Capital Management, LLC

    0.82%

  • Northern Trust Corp

    0.40%

  • Royal Bank of Canada

    0.24%

Company Information

our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. the pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. the team is complemented by world-class medical advisors. our products have been organically conceived, researched and developed by the company and all manufacturing activities are conducted to ensure compliance with the u.s. food and drug administration (fda) per the requirements of 21 cfr 820, as well as iso 13485. femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the u.s. food and drug administration (fda), european union, canada, and japan with other select countries in process. making a difference in t

Organization
Femasys Inc
Employees
32
CEO
Ms. Kathy Lee-Sepsick M.B.A.
Industry
Miscellaneous

Discover More

FAQs